Compare DLNG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | SCLX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.4M | 139.3M |
| IPO Year | 2013 | N/A |
| Metric | DLNG | SCLX |
|---|---|---|
| Price | $3.82 | $17.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.6K | ★ 121.1K |
| Earning Date | 11-20-2025 | 11-14-2025 |
| Dividend Yield | ★ 5.22% | N/A |
| EPS Growth | ★ 30.14 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $158,275,000.00 | $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.37 | $749.70 |
| P/E Ratio | $2.91 | ★ N/A |
| Revenue Growth | ★ 4.34 | N/A |
| 52 Week Low | $3.18 | $3.60 |
| 52 Week High | $5.65 | $34.27 |
| Indicator | DLNG | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 44.15 |
| Support Level | $3.71 | $18.34 |
| Resistance Level | $3.84 | $20.62 |
| Average True Range (ATR) | 0.11 | 2.20 |
| MACD | 0.01 | -0.29 |
| Stochastic Oscillator | 96.05 | 2.90 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.